Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Collegium Pharmaceutical Inc., 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
118.8% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Collegium Pharmaceutical Inc. May 16, 202499.2%
-
Zevra Therapeutics Inc. May 13, 202458.2%
-
Collegium Pharmaceutical Inc. May 18, 202399.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 12, 2026 | Zevra Therapeutics Inc. | Open-market sale | −20,000 | $11.25 | $224,948 |
| Oct 10, 2026 | Zevra Therapeutics Inc. | Option exercise | +50,000 | — | — |
| Feb 9, 2026 | Zevra Therapeutics Inc. | Open-market sale | −14,625 | $8.56 | $125,190 |
| Feb 7, 2026 | Zevra Therapeutics Inc. | Option exercise | +37,500 | — | — |
| Feb 2, 2026 | Zevra Therapeutics Inc. | Open-market sale | −91,000 | $9.38 | $853,580 |
| Jan 31, 2026 | Zevra Therapeutics Inc. | Option exercise | +233,334 | — | — |
| Oct 10, 2025 | Zevra Therapeutics Inc. | Option exercise | +50,000 | — | — |
| Oct 10, 2025 | Zevra Therapeutics Inc. | Open-market sale | −19,500 | $10.82 | $210,990 |
| Feb 14, 2025 | Zevra Therapeutics Inc. | Open-market sale | −30,544 | $8.05 | $245,879 |
| Feb 13, 2025 | Zevra Therapeutics Inc. | Open-market sale | −61,273 | $7.86 | $481,606 |
| Jan 31, 2025 | Zevra Therapeutics Inc. | Option exercise | +233,333 | — | — |
| May 16, 2024 | Collegium Pharmaceutical Inc. | Grant or award | +7,693 | — | — |
| May 18, 2023 | Collegium Pharmaceutical Inc. | Grant or award | +9,792 | — | — |
Questions about Neil F. McFarlane
What boards is Neil F. McFarlane on?
Neil F. McFarlane sits on the boards of Collegium Pharmaceutical Inc. and Zevra Therapeutics Inc.
What company is Neil F. McFarlane the CEO of?
Neil F. McFarlane has been President and CEO of Zevra Therapeutics Inc. since October 2023.
How long has Neil F. McFarlane served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.